SI3735267T1 - Dajanje več bolusov (6R) MTHF pri kemoterapiji na osnovi 5-fluorouracila - Google Patents

Dajanje več bolusov (6R) MTHF pri kemoterapiji na osnovi 5-fluorouracila

Info

Publication number
SI3735267T1
SI3735267T1 SI201930415T SI201930415T SI3735267T1 SI 3735267 T1 SI3735267 T1 SI 3735267T1 SI 201930415 T SI201930415 T SI 201930415T SI 201930415 T SI201930415 T SI 201930415T SI 3735267 T1 SI3735267 T1 SI 3735267T1
Authority
SI
Slovenia
Prior art keywords
mthf
fluorouracil
administration
based chemotherapy
multiple boluses
Prior art date
Application number
SI201930415T
Other languages
English (en)
Inventor
Karin Ganlov
Magnus Ostberg
Per L. Lindberg
Gunnel E. Sunden
Bengt Gustavsson
Original Assignee
Isofol Medical AB, Biotech Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/050274 external-priority patent/WO2019037899A1/en
Application filed by Isofol Medical AB, Biotech Center filed Critical Isofol Medical AB, Biotech Center
Publication of SI3735267T1 publication Critical patent/SI3735267T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SI201930415T 2018-01-05 2019-01-04 Dajanje več bolusov (6R) MTHF pri kemoterapiji na osnovi 5-fluorouracila SI3735267T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2018/050274 WO2019037899A1 (en) 2017-08-24 2018-01-05 ADMINISTRATION OF MULTIPLE [6R] -MTHF BOLUSES DURING CHEMOTHERAPY BASED ON 5-FLUORO-URACILE
US201862651910P 2018-04-03 2018-04-03
US201862769289P 2018-11-19 2018-11-19
PCT/IB2019/000008 WO2019135157A1 (en) 2018-01-05 2019-01-04 Methods for treating colorectal and metastatic colorectal cancers
EP19705386.1A EP3735267B8 (en) 2018-01-05 2019-01-04 Administration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy

Publications (1)

Publication Number Publication Date
SI3735267T1 true SI3735267T1 (sl) 2023-04-28

Family

ID=67143641

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201930415T SI3735267T1 (sl) 2018-01-05 2019-01-04 Dajanje več bolusov (6R) MTHF pri kemoterapiji na osnovi 5-fluorouracila

Country Status (15)

Country Link
EP (1) EP3735267B8 (sl)
JP (1) JP7258759B2 (sl)
KR (1) KR20200107988A (sl)
CN (1) CN110573178A (sl)
AU (1) AU2019205861A1 (sl)
CA (1) CA3087514A1 (sl)
DK (1) DK3735267T3 (sl)
ES (1) ES2933266T3 (sl)
HU (1) HUE061217T2 (sl)
IL (1) IL275805A (sl)
MX (1) MX2020007009A (sl)
SG (1) SG11202006436SA (sl)
SI (1) SI3735267T1 (sl)
TW (1) TW201929901A (sl)
WO (1) WO2019135157A1 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110538316B (zh) * 2019-10-17 2021-10-15 滨州医学院 5-fu和胰高血糖素联合用于制备治疗结直肠癌的药物的用途和药物组合物
WO2021185234A1 (zh) * 2020-03-16 2021-09-23 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
WO2023046307A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer
WO2023046304A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer
WO2023046305A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer
US20230095428A1 (en) * 2021-09-28 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer
US20230097085A1 (en) * 2021-09-28 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer
CN114522227B (zh) * 2022-01-24 2023-02-07 中山大学附属第六医院 一种治疗局部晚期微卫星稳定型结直肠癌的药物组合物以及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005231436A1 (en) * 2004-04-02 2005-10-20 Adventrx Pharmaceuticals, Inc. Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
CN101321518A (zh) * 2005-12-02 2008-12-10 阿德文特克斯药物有限公司 5,10-亚甲基四氢叶酸盐的稳定药物组合物
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid

Also Published As

Publication number Publication date
EP3735267B8 (en) 2022-11-09
EP3735267A1 (en) 2020-11-11
DK3735267T3 (da) 2022-12-12
RU2020122373A (ru) 2022-02-07
KR20200107988A (ko) 2020-09-16
CA3087514A1 (en) 2019-07-11
TW201929901A (zh) 2019-08-01
EP3735267B1 (en) 2022-09-14
MX2020007009A (es) 2020-11-11
AU2019205861A1 (en) 2020-08-06
SG11202006436SA (en) 2020-08-28
JP2021510140A (ja) 2021-04-15
HUE061217T2 (hu) 2023-05-28
WO2019135157A1 (en) 2019-07-11
CN110573178A (zh) 2019-12-13
ES2933266T3 (es) 2023-02-03
IL275805A (en) 2020-08-31
JP7258759B2 (ja) 2023-04-17

Similar Documents

Publication Publication Date Title
SI3735267T1 (sl) Dajanje več bolusov (6R) MTHF pri kemoterapiji na osnovi 5-fluorouracila
EP3432926A4 (en) METHODS OF REDUCING THE TOXICITY OF A CHEMOTHERAPEUTIC MEDICAMENT
EP3490564A4 (en) MACRO CYCLE Kinase Inhibitors
IL258920B (en) The device with two vial adapters includes a drug vial adapter with a self-sealing access valve
EP3286003A4 (en) Fluid ejection devices with reduced crosstalk
IL272876B (en) Repeated administration of large doses of [6r]-mthf in 5-fluorouracil chemotherapy
EP3398047A4 (en) PROVIDING ROLLING UPDATES OF DISTRIBUTED SYSTEMS WITH A COMMON CACHE MEMORY
EP3479828A4 (en) MEDICINAL COMPOSITION FOR PARENTERAL ADMINISTRATION
ZA201808014B (en) Adenine derivatives as protein kinase inhibitors
EP3445347A4 (en) IMPROVEMENT OF CHEMOTHERAPY
EP3315501A4 (en) ANTIVIRAL ACTION MEDICINE (VARIANTS)
EP3572081A4 (en) ANTIVIRAL MEDICINE FOR HIGH FEVER WITH THROMBOCYTOPENIA SYNDROME
EP3395363A4 (en) ANTIVIRAL MEDICINAL PRODUCT
EP3264941A4 (en) Adjustable floating shelving systems
EP3875089A4 (en) TABLET CONTAINING AN ANTI-TUMOR AGENT
EP3618837A4 (en) MULTI-DIRECTIONAL NUCLEOSIDE DERIVATIVES
HK1250641A1 (zh) 用於腸胃外給藥的維生素a
EP3589372A4 (en) COMPOSITION OF CHEMOTHERAPEUTIC DRUG
EP3646869A4 (en) AZABICYCLOVA-LINKED CANCER CHEMOTHERAPY
EP3584023A4 (en) HORIZONTAL TOWER
IL272874A (en) [6R]-MTHF as an effective folate substitute in 5-fluorouracil chemotherapy
GB201910459D0 (en) Pocket Nebuliser
GB201910384D0 (en) Pocket nebuliser
EP3860591A4 (en) PRE-ACTIVATED NUCLEOSIDE IMPDH INHIBITORS AS ANTI-INFECTIVE DRUGS
ZAA201801964S (en) My true north set